TAILIEUCHUNG - Báo cáo khoa hoc:" Tolerance and rebound with zafirlukast in patients with persistent asthma"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Tolerance and rebound with zafirlukast in patients with persistent asthma | Journal of Negative Results in BioMedicine BioMed Central Research Tolerance and rebound with zafirlukast in patients with persistent asthma David W Reid 1 Neil L Misso2 Shashi Aggarwal2 Philip J Thompson2 David P Johns1 and E Haydn Walters1 Open Access Address Respiratory Research Group Menzies Research Institute University of Tasmania Hobart Tasmania Australia and 2Lung Institute of Western Australia Centre for Asthma Allergy Respiratory Research The University of Western Australia Perth Australia Email David W Reid - Neil L Misso - nmisso@ Shashi Aggarwal - saggrawal@ Philip J Thompson - pjthomps@ David P Johns - E Haydn Walters - Corresponding author Published 19 May 2008 Received II May 2007 Journal of Negative Results in BioMedicine 2008 7 3 doi 1477-5751-7-3 Accepted 19 May 2008 This article is available from http content 7 1 3 2008 Reid et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The potential for tolerance to develop to zafirlukast a cysteinyl leukotriene CysLT receptor antagonist LRA in persistent asthma has not been specifically examined. Objective To look for any evidence of tolerance and potential for short-term clinical worsening on LRA withdrawal. Outcome measures included changes in airway hyperresponsiveness to inhaled methacholine PD20FEV1 daily symptoms and peak expiratory flows PEF sputum and blood cell profiles sputum CysLT and prostaglandin PG E2 and exhaled nitric oxide eNO levels. Methods A double blind placebo-controlled study of zafirlukast 20 mg twice daily over 12 weeks in 21 asthmatics taking P2-agonists only Group I and 24 .

TÀI LIỆU LIÊN QUAN
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.